Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Palatin has initiated dosing in a Phase I trial of a long acting analog of atrial natriuretic peptide for the treatment of acute decompensated congestive heart failure.
Subscribe to our email newsletter
The study will be performed in healthy volunteers who will receive the drug subcutaneously. The evaluations will include safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including endogenous messenger levels such as cyclic guanosine monophosphate.
Dr Trevor Hallam, Palatin’s executive vice president for R&D, said: “We are excited to begin clinical trials of PL-3994, a compound developed by Palatin scientists that has the potential to become a new tool for physicians to advance the treatment of congestive heart failure (CHF). CHF is the single most common cause of hospitalization in the US for patients older than 65 years of age and an underserved medical condition.”